Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interferons in the treatment of myeloproliferative neoplasms.
Vachhani P, Mascarenhas J, Bose P, Hobbs G, Yacoub A, Palmer JM, Gerds AT, Masarova L, Kuykendall AT, Rampal RK, Mesa R, Verstovsek S. Vachhani P, et al. Ther Adv Hematol. 2024 Feb 19;15:20406207241229588. doi: 10.1177/20406207241229588. eCollection 2024. Ther Adv Hematol. 2024. PMID: 38380373 Free PMC article. Review.
Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration.
Jain T, Tsai HL, Elmariah H, Vachhani P, Karantanos T, Wall S, Gondek L, Bashey A, Keyzner A, Tamari R, Grunwald M, Abedin S, Nadiminti K, Iqbal M, Gerds A, Viswabandya A, McCurdy S, Malki MA, Varadhan R, Ali H, Gupta V, Jones RJ, Otoukesh S. Jain T, et al. Among authors: vachhani p. Res Sq [Preprint]. 2023 Mar 21:rs.3.rs-2691216. doi: 10.21203/rs.3.rs-2691216/v1. Res Sq. 2023. Update in: Haematologica. 2023 Dec 01;108(12):3321-3332. doi: 10.3324/haematol.2023.283426 PMID: 36993719 Free PMC article. Updated. Preprint.
Avapritinib versus Placebo in Indolent Systemic Mastocytosis.
Gotlib J, Castells M, Elberink HO, Siebenhaar F, Hartmann K, Broesby-Olsen S, George TI, Panse J, Alvarez-Twose I, Radia DH, Tashi T, Bulai Livideanu C, Sabato V, Heaney M, Van Daele P, Cerquozzi S, Dybedal I, Reiter A, Pongdee T, Barete S, Ustun C, Schwartz L, Ward BR, Schafhausen P, Vadas P, Bose P, DeAngelo DJ, Rein L, Vachhani P, Triggiani M, Bonadonna P, Rafferty M, Butt NM, Oh ST, Wortmann F, Ungerstedt J, Guilarte M, Taparia M, Kuykendall AT, Arana Yi C, Ogbogu P, Gaudy-Marqueste C, Mattsson M, Shomali W, Giannetti MP, Bidollari I, Lin HM, Sulllivan E, Mar B, Scherber R, Roche M, Akin C, Maurer M. Gotlib J, et al. Among authors: vachhani p. NEJM Evid. 2023 Jun;2(6):EVIDoa2200339. doi: 10.1056/EVIDoa2200339. Epub 2023 May 23. NEJM Evid. 2023. PMID: 38320129 Clinical Trial.
Real-World Treatment Patterns and Healthcare Resource Use for Patients with Myelofibrosis: Results from the METER Study.
Gupta V, Tomuleasa C, Barranco G, Hou HA, Helbig G, Vachhani P, Symeonidis A, Haznedaroglu IC, Galvez K, Tatsch F, Chopra AS, Zhang M, Vizkelety T, Murray BC, Ross DM. Gupta V, et al. Among authors: vachhani p. Blood Adv. 2024 Dec 27:bloodadvances.2024014625. doi: 10.1182/bloodadvances.2024014625. Online ahead of print. Blood Adv. 2024. PMID: 39729499
Investigational drugs in early phase trials for myelofibrosis.
Arora S, Vachhani P, Bose P. Arora S, et al. Among authors: vachhani p. Expert Opin Investig Drugs. 2024 Dec;33(12):1231-1244. doi: 10.1080/13543784.2024.2434696. Epub 2024 Nov 27. Expert Opin Investig Drugs. 2024. PMID: 39604120 Review.
Ruxolitinib for myelofibrosis: The earlier, the better?
Bose P, Vachhani P. Bose P, et al. Among authors: vachhani p. Cancer. 2024 Dec 15;130(24):4224-4226. doi: 10.1002/cncr.35592. Epub 2024 Oct 13. Cancer. 2024. PMID: 39396121 No abstract available.
Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis.
Tefferi A, Barosi G, Passamonti F, Hernandez-Boluda JC, Bose P, Döhner K, Ellis M, Gangat N, Garcia JS, Gisslinger H, Gotlib J, Guglielmelli P, Gupta V, Harrison C, Hexner EO, Hobbs GS, Kiladjian JJ, Koschmieder S, Kroger N, Kuykendall AT, Loscocco GG, Mascarenhas J, Masarova L, Mesa R, Mora B, Odenike O, Oh ST, Pardanani A, Patel A, Pemmaraju N, Rambaldi A, Rampal R, Sirhan S, Szuber N, Talpaz M, Vachhani PJ, Vannucchi AM, Barbui T. Tefferi A, et al. Among authors: vachhani pj. Blood. 2024 Oct 24;144(17):1813-1820. doi: 10.1182/blood.2024025802. Blood. 2024. PMID: 39116296
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.
Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, Racevskis J, Lazarus HM, Rowe JM, Arber DA, Wieduwilt MJ, Liedtke M, Bergeron J, Wood BL, Zhao Y, Wu G, Chang TC, Zhang W, Pratz KW, Dinner SN, Frey N, Gore SD, Bhatnagar B, Atallah EL, Uy GL, Jeyakumar D, Lin TL, Willman CL, DeAngelo DJ, Patel SB, Elliott MA, Advani AS, Tzachanis D, Vachhani P, Bhave RR, Sharon E, Little RF, Erba HP, Stone RM, Luger SM, Mullighan CG, Tallman MS. Litzow MR, et al. Among authors: vachhani p. N Engl J Med. 2024 Jul 25;391(4):320-333. doi: 10.1056/NEJMoa2312948. N Engl J Med. 2024. PMID: 39047240 Clinical Trial.
79 results